PT - JOURNAL ARTICLE AU - Jonathan I.D. Hamley AU - David J. Blok AU - Martin Walker AU - Philip Milton AU - Adrian D. Hopkins AU - Louise C. Hamill AU - Philip Downs AU - Sake J. de Vlas AU - Wilma A. Stolk AU - Maria-Gloria Basáñez TI - What does the COVID-19 pandemic mean for the next decade of onchocerciasis control and elimination? AID - 10.1101/2020.10.26.20219733 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.26.20219733 4099 - http://medrxiv.org/content/early/2020/10/27/2020.10.26.20219733.short 4100 - http://medrxiv.org/content/early/2020/10/27/2020.10.26.20219733.full AB - Background Mass drug administration (MDA) of ivermectin for onchocerciasis has been disrupted by the SARS-CoV-2 (COVID-19) pandemic. Mathematical modelling can help predict how missed/delayed MDA will affect short-term epidemiological trends and elimination prospects by 2030.Methods Two onchocerciasis transmission models (EPIONCHO-IBM and ONCHOSIM) are used to simulate microfilarial prevalence trends, elimination probabilities, and age-profiles of Onchocerca volvulus microfilarial prevalence and intensity, for different treatment histories and transmission settings, assuming no interruption, a 1-year (2020) or 2-year (2020–2021) interruption. Biannual MDA or increased coverage upon MDA resumption are investigated as remedial strategies.Results Programmes with shorter MDA histories and settings with high pre-intervention endemicity will be the most affected. Biannual MDA is more effective than increasing coverage for mitigating COVID-19’s impact on MDA. Programmes which had already switched to biannual MDA should be minimally affected. In high transmission settings with short treatment history, a 2-year interruption could lead to increased microfilarial load in children (EPIONCHO-IBM) or adults (ONCHOSIM).Conclusions Programmes with shorter (annual MDA) treatment histories should be prioritised for remedial biannual MDA. Increases in microfilarial load could have short- and long-term morbidity and mortality repercussions. These results can guide decision-making to mitigate the impact of COVID-19 on onchocerciasis elimination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Bill and Melinda Gates Foundation via the NTD Modelling Consortium (grant number OPP1184344); the UK Medical Research Council (MRC Doctoral Training Programme award to PM); MRC and the UK Department for International Development (DFID) Joint Centre Funding under the MRC/DFID Concordat agreement of the European Union and European and Developing Countries Clinical Trials Partnership 2 (grant number MR/R015600/1 (JIDH, PM, MGB).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable. This is a modelling study and no data are used.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData availability statement: No new data were used in this study. The model code is available on Github.ABRannual biting rateAPOCAfrican Programme for Onchocerciasis ControlEOTelimination of transmissionIBMindividual-based modelMDAmass drug administrationaMDAannual mass drug administrationbMDAbiannual mass drug administrationMDPMectizan Donation ProgramNTDneglected tropical diseaseOCPOnchocerciasis Control Programme in West AfricaPCTpreventive chemotherapy and transmission controlUSAIDUnited States Agency for International DevelopmentWHOWorld Health Organization.